Specialist nurse-led perioperative nursing care for head and neck cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares a multidisciplinary specialist nurse-led perioperative nursing management program plus routine care to routine perioperative care alone for head and neck cancer surgery patients. The intervention uses comprehensive preoperative assessments, individualized care planning, ongoing follow-up, and quality assurance with interprofessional collaboration. Outcomes include postoperative complications, nutritional status, quality of life, nursing satisfaction, length of stay, and costs. The trial is conducted at Tianjin Medical University Cancer Institute and Hospital in China and builds on evidence-based literature and expert consensus. Participants are adults with head and neck cancer scheduled for surgery, excluding those with severe comorbidity or limited life expectancy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with head and neck cancer according to the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Head and Neck Tumors (2023)
* Patients scheduled to undergo head and neck cancer surgery
* Age \>18 years
* Patients who fully understand the study and voluntarily agree to participate

Exclusion Criteria:

* Patients with severe cardiovascular diseases, uncontrolled infections, or other diseases or complications that could affect study participation
* Patients with an estimated survival time of less than 6 months based on tumor stage and overall health status

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: jiayan Cao
• Email: Caojiayan_1976@126.com
• Phone: 86+23340123-3130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton Re-irradiation for Recurrent or Second Primary Head and Neck Cancer

  This study tests proton radiotherapy to see if it can control head and neck cancer that has come back or appeared again in the same area, while trying to limit side effects.

  Recruiting Oslo University Hospital · Bergen and 3 other locations · NCT07922967

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer

  A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.

  Recruiting at 9 sites Phase 3 OncoZenge AB · Copenhagen and 10 other locations · NCT07672236

• Proton Re-irradiation for Head and Neck Cancer Recurrence

  This study tests whether proton therapy as a second round of radiation is safe and helpful for adults with head and neck cancer that has come back after prior treatment.

  Recruiting Istituto Clinico Humanitas · Rozzano, Milano · NCT07635641

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.